Please Wait.....
Report
Artificial Lung Devices-Pipeline Insight and Competitive Landscape, 2022
Medical Pipeline (24 Hours) I 2022-07-01 I 60 Pages I DelveInsight
DelveInsight's, "Artificial Lung Devices-Pipeline Insight and 2022," report provides comprehensive insights about 20+ companies and 23+ pipeline devices in artificial lung devices pipeline landscape. Globally, number of cases related to respiratory failure and cardiopulmonary collapse has grown rapidly. This has resulted in increasing demand for artificial lung that acts as an external support system providing oxygenation of blood and removal of carbon dioxide from the blood. Researcher and scientists are also making persistent efforts in developing and improving artificial lung, with which it can be used at larger scale and with greater ease. Therefore, due to an increase in demand and more and more players investing in research and development activities there is an extensive pipeline of artificial lung devices.
DeleveInsight latest report has all the emerging artificial lung devices along with competitive landscape to help better understand the market scenario.
Artificial Lung Devices Overview
Artificial Lung Devices: Understanding
Artificial lung device is a prosthetic device works as an alternative to the biological lung. It provides oxygenation of blood and removal of carbon dioxide from the blood. Artificial lung devices are made of synthetic material that are connected to blood vessels through tubes and cannulas of silicone.
Who needs Artificial Lungs?
- Chronic obstructive pulmonary diseases (COPD) patients
- Idiopathic interstitial pneumonia (IIPs)
- Cystic Fibrosis (CF)
- Pulmonary Arterial Hypertension
Artificial Lungs Devices: Competitive Assessment
This segment of the artificial lung devices report encloses its detailed analysis of various pipeline devices which include product description, licensing and collaboration details and other developmental activities including latest news and press releases. The report also provides list of major players involved in the pipeline product development.
?
- Product Type
Artificial lung devices for decades have been used in newborns and children with lung failure, pneumonia, meconium aspiration syndrome and other conditions. However, recently they have also been employed to be used in adults. Hence the segmentation of the report categories device products based on pediatric, adult, both.
- Product Technology
Artificial lung devices can be used in two different ways - venovenous (VV) and venoarterial (VA), both the ways are covered in the report.
- Approval
The assessment has been carried out on the basis of artificial lung device approval- FDA, CE Mark or both.
- Stage
The competitive assessment of the pipeline devices has been given pertaining to their stage, whether they are in the clinical or the pre-clinical stage.
- Major Players in Artificial Lung Devices
There are approx. 20+ key companies which are developing the products for artificial lung devices.
- Hemolung RAS: ALung Technologies, Inc
Hemolung RAS provides ultra-low-flow, veno-venous extracorporeal carbon dioxide removal (ECCO2R) using a single, 15.5 French dual lumen catheter inserted percutaneously in the femoral or jugular vein. Low-flow ECCO2R with the Hemolung RAS provides partial lung support independently of the lungs. The Hemolung RAS removes 25% - 50% of basal metabolic CO2 production at circuit blood flows of 350-550 mL/min. The Hemolung RAS is designed to minimize the complication risks associated with extracorporeal gas exchange therapy.
- OXY-1: Breethe, Inc
Breethe's system, called the OXY-1 System, is designed to remove carbon dioxide and add oxygen to a patient's blood, much like a working human lung would. The tech eliminates the need for bulky oxygen tanks, and allows patients in need of ECMO therapy to move around more easily. Breethe has filed for clearance from the U.S. Food and Drug Administration for the OXY-1 System, but has not yet received it.
- Xenolungs: Lung Biotechnology
Lung Biotechnology is actively progressing towards the research and development of xenolungs. They have been constantly trying to develop new technologies and products to alleviate access and improve outcomes in patients that are suffering from Pulmonary Arterial Hypertension (PAH) and other fatal diseases. Xenolungs are human-compatible lungs that are developed in genetically engineered pigs. The patients receiving lung transplants have an improved quality of life and higher chances of survival.
Further product details are provided in the report..
Artificial Lung Devices - Competitive Assessment
This segment of the report provides a brief competitive analysis of Artificial Lung Devices, to help understand the competition in the market. It gives a comparative understanding of the Artificial Lung Devices based on parameters such patient type.
Artificial Lung Devices: Competitive Benchmarking
This segment of the reports provides analysis of the pipeline report to give a clear understanding of the comparative analysis.
The analysis is based on
- Brand Positioning of Leading companies
- Industry Collaborations
Artificial Lung Devices: Commercialization Activity
This segment of the report provides a detailed list of any commercial activity in the field of artificial lung devices ranging from collaboration, mergers and acquisition, recent breakthrough among others.
Development Activities
- In April, 2015, Breethe, Inc. announced to obtained exclusive rights to University of Maryland, Baltimore (UMB) intellectual property (IP) for the development of a wearable, portable blood pump oxygenator that will function as an artificial lung system for patients suffering from respiratory failure and cardiopulmonary collapse.
- On February 08, 2017, Miromatrix Medical received an innovative technology contract from Vizient Inc. for their Miromesh and Miroderm products. Vizient, Inc. is the largest member-owned healthcare company that is devoted to providing healthcare innovations (MIROMATRIX MEDICAL Inc, 2017).
- In December 2020, Abiomed announced that it has treated two patients in the world with the AbiomedBreethe OXY-1 System, a compact cardiopulmonary bypass system. It is an advanced ECMO technology along with pumps and oxygenator that removes carbon dioxide from the blood for patients whose lungs can no longer provide sufficient organ (ABIOMED, Inc., 2020).
Further commercial activities are provided in the report..
.
Artificial Lung Devices: Reimbursement
- US
In 2018, Centers for Medicare and Medicaid Services (CMS) implemented a series of coding categories and qualifiers for extracorporeal membrane oxygenation (ECMO) care, also known as artificial lungs. Among them, exclusion of veno-venous (VV) ECMO from DRG 003 heralds significant reimbursement reductions that may threaten fiscal viability of ECMO programs. This case series analysis evaluates merits and pitfalls of altering ECMO reimbursement.
Further information is provided in the report..
Report Highlights
- Extensive coverage of the artificial lung devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of artificial lung devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
- The report consists of in depth analysis of pipeline products based on various parameters
Artificial Lung Devices Report Insights
- Artificial Lung Devices - Pipeline Analysis
- Artificial Lung Devices - Unmet Need
- Artificial Lung Devices - Market Dynamics
- Artificial Lung Devices - Future Perspectives and Conclusion
- Artificial Lung Devices- Analyst Views
Key Questions
- What are significant companies in this segment, their information, analysis, and insights to improve R&D strategies?
- How to identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage?
- What are important and diverse types of artificial lung devices under development?
- What are market-entry and market expansion strategies in artificial lung devices?
- What are some of the mergers and acquisitions and to identify major players with the most promising pipeline?
- What is in-depth analysis of the product's current stage of development, territory and estimated launch date?
Key Players
- Lung Biotechnology
- Miromatrix
- Charles Stark Draper Laboratory Inc
- United Therapeutics Corporation
- XVIVO Perfusion
- Medtronic
- Getinge
- Xenios AG
- ALung Technologies Inc.
- MC3 Cardiopulmonary
- Abiomed
1 Key Insights
2 Artificial Lung Devices: Snapshot
3 Artificial Lung Devices: Background and Overview
3.1 Introduction
3.1.1 Cardiopulmonary Bypass (CPB)
3.1.2 Extracorporeal Membrane Oxygenation (ECMO)
3.1.3 Xenotransplantation
3.1.4 3D bio-printed lungs
3.2 Location of Artificial Lung Devices
3.3 Mechanism of Artificial Lung Device
3.4 Clinical Application of Artificial Lung Devices
3.4.1 Chronic obstructive pulmonary disease (COPD)
3.4.2 Idiopathic interstitial pneumonia (IIPs)
3.4.3 Cystic Fibrosis (CF)
3.4.4 Pulmonary Arterial Hypertension
3.5 Nomenclature and Competition in ALD
4 Product Profiling
4.1 ALD Pipeline Devices
4.1.1 Xenolung
4.1.2 Perfusion Decellularization of Lungs
4.1.3 Artificial Lung Technology
4.1.4 Total Artificial Lung (TAL)
4.1.5 U-Lung
4.2 ALD Marketed Devices
4.2.1 XVIVO Perfusion System (XPS) with STEEN Solution Perfusate
4.2.2 Quadrox-ID Pediatric oxygenator
4.2.3 Affinity NT
4.2.4 HLS Set Advanced
4.2.5 Novalung ILA System
4.2.6 Hemolung RAS
4.2.7 The Nautilus Smart ECMO Module
4.2.8 Abiomed Breethe OXY-1 System
5 Artificial Lung Devices: Competitive Assessment of Listed Products
5.1 Competitive Assessment of Listed Pipeline Devices
5.1.1 Assessment Based on Stage
5.2 Competitive Assessment of Listed Marketed Devices
5.2.1 Assessment Based on Patient Type
5.2.2 Assessment Based on Approval
5.2.3 Assessment Based on Route of Implantation
5.3 Competitive Assessment between Listed Pipeline and Marketed Devices
5.3.1 Assessment Based on Pipeline vs Marketed Devices
6 Artificial Lung Devices: Competitive Benchmarking: By Company
6.1 Brand Positioning of Leading Companies
6.2 Analysis based on Industry Collaborations
7 Artificial Lung Devices - Commercialization Activity
7.1 Collaboration
7.2 Licensing
7.3 Merger and Acquisition
7.4 Recent Breakthroughs
7.5 Literature Studies
7.6 KOL Views
8 Artificial Lung Devices: Regulatory Overview
8.1 United States Regulation of Devices
8.2 European Regulation of Devices
8.3 Japan Regulation of Devices
9 Artificial Lung Devices: Reimbursement
9.1 United States
9.2 Europe
9.3 Japan
10 Artificial Lung Devices: Market Dynamics
10.1 Unmet Needs
10.2 Market Drivers
10.3 Market Barriers
11 DelveInsight's Analytical Perspective
11.1 PEST Analysis
12 Conclusion & Future Growth Perspectives
13 Appendix
13.1 Bibliography
14 Report Methodology
15 DelveInsight Capabilities
16 Disclaimer
17 About DelveInsight
Table 1: Differences between ECMO and CPB
Table 2: List of ALD Pipeline Devices
Table 3: List of ALD Marketed Devices
Table 4: Competitive Assessment Based on Stage
Table 5: Competitive Assessment for Marketed Devices
Table 6: Competitive Assessment Based on Pipeline vs Marketed Devices
Table 7: Analysis based on Industry Collaborations
Table 8: Pipeline Product Profiling (Academia)
Figure 1: The placement of Artificial lung devices
Figure 2: Cardiopulmonary bypass (CPB) machine
Figure 3: Standard V-A ECMO circuit.
Figure 4: Central and peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO) strategies
Figure 5: VenoveneousExtracorporeal Membrane Oxygenation (VV-ECMO)
Figure 6: Artificial Lung Devices Mechanism
Figure 7: Product Specifications of the XVIVO Perfusion System (XPS) with STEEN Solution
Figure 8: The MaquetQuadrox-ID Pediatric oxygenator
Figure 9: The Affinity NT
Figure 10: The HLS Set Advanced
Figure 11: The Novalung ILA System
Figure 12: Hemolung RAS
Figure 13: The Nautilus Smart ECMO Module
Figure 14: AbiomedBreethe OXY-1 System
Figure 15: Assessment Based on Stage
Figure 16: Assessment Based on Patient Type
Figure 17: Assessment Based on Approval
Figure 18: Assessment Based on Route of Implantation
Figure 19: Assessment Based on Pipeline vs Marketed Devices
Figure 20: Comparison of Device Approval Processes in the United States and EU
Figure 21: Device Approval Processes in Japan
Figure 22: Assessment Based on Stage
Figure 23: Market Drivers
Figure 24: Market Barriers
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security